Churg-Strauss syndrome with montelukast

The case report by Tuggey and Hosker is similar to many of the cases of Churg-Strauss syndrome (CSS) which we have reported in association with zafirlukast, montelukast, and fluticasone/salmeterol. It also shares many similarities with the reports of CSS with inhaled steroid monotherapy.1,2,3,4

While a temporal relationship with the use of leukotriene modifiers is being reported with increased frequency in association with CSS, a review of this case and others in the literature does not suggest a direct causal relationship with the leukotriene modifiers. Rather, two systemic syndromes seem to predominate. In the first, CSS develops following steroid withdrawal as a result of, or concomitant with, leukotriene modifier use in patients who probably had what was perceived to be severe asthma but was likely to have been CSS masked by steroids (forme fruste CSS). A second mechanism is typified by patients not tapered from systemic steroids. These patients, of which the patient in this case report seems to be an example, have worsening underlying asthma symptoms as the heralding sign of incipient CSS. While, in the past, systemic steroids would have been used to treat this worsening prodromal allergic asthma phase, the recent availability of high dose inhaled steroid therapy and leukotriene modifiers has led to a decrease or delay in systemic steroid prescription for these patients. While this could initially mask the syndrome due to adequate systemic absorption or local airway effects, as the disease progresses they may not have the potency to combat this systemic vasculitides—often not enough and other cytotoxic agents are required. Similarly, leukotriene modifiers may initially be added in lieu of steroids for treatment of signs of airway obstruction as the disease is not recognized as CSS. To date, all cases in the literature of CSS in association with asthma treatment fulfil one of these scenarios. The coincidental institution of these treatments near the time of worsening of the syndrome does not imply causality; rather, these new drugs seem to be unmasking the syndrome and showing that this disease is not as rare as was once perceived. While not all severe asthma is CSS, physicians should recognize worsening asthma in the setting of increased steroid therapy as a potential heralding sign of CSS and look for other vasculitic sequelae.

MICHAEL WECHSLER
Pulmonary and Critical Care Division, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
mwechsler@rics.bwh.harvard.edu

AUTHORS’ REPLY We agree with Dr Wechsler that it is possible that our patient’s asthma was deteriorating as a result of treatment with Churg-Strauss syndrome (CSS). He is right to remind physicians that CSS is one of several causes of worsening asthma. However, we are not sure that it is equally important to question whether the development of CSS is causally related to the recent prescription of a relatively new class of drug. Whatever the mechanism, physicians should be aware of the possible risk of CSS associated with the introduction of anti-leukotrienes and other therapies and should report all suspected cases to their national drug surveillance authority.

MICHAEL J TUGGEY
H S R HOSKER
Department of Respiratory Medicine, St James’s University Hospital, Leeds LS9 7TF, UK
justin@tuggey.demon.co.uk

Malignant mesothelioma

We wish to suggest a minor correction to the otherwise excellent editorial by Drs Steele and Rudd in your recent issue.1 The status of the forthcoming British Thoracic Society study of the management of malignant mesothelioma is that this study is being supported by the British Thoracic Society and the pilot study is being assisted by the Clinical Trials Unit of the Medical Research Council. Funding for the whole of the Medical Research Council Staff has been obtained through the BTS Scientific Committee and from two independent mesothelioma charities—The June Hancock Mesothelioma Research Fund and the Anthony Farmer Mesothelioma Research Fund. We have approached the Medical Research Council with a bid for full funding of the final study but the outcome of the application is not yet known.

MARTIN F MUERS
Department of Respiratory Medicine, Leeds General Infirmary, Leeds LS1 3EX, UK

DAVID J GIRLING
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK


Assisted discharge for patients with exacerbations of COPD

We read with interest the recent papers which report the findings of randomised controlled trials of early supported discharge for patients with exacerbations of chronic obstructive pulmonary disease (COPD). Both

found that a proportion of such patients presenting to hospital could be safely cared for at home with respiratory nurse support, without adversely affecting mortality or readmission rates.

A similar service to those described operated for the first time in Sheffield over the winter of 1997/8, supported by government money to ease the demand for beds during the winter. Although this did not involve randomising, our findings were essentially similar. Unselected patients with exacerbations referred by general practitioners for admission to hospital were reviewed and those fulfilling the British Thoracic Society guidelines for early supported discharge were offered home treatment. Over a 4 month period 29 of 118 patients (25%) referred were found to be suitable for supported discharge, and we successfully treated the 22 patients who consented to participate. Although this is only a small number of patients, there were no readmissions and no home deaths. The remaining 89 patients required admission because of respiratory complications (21 hypoxia, 10 pneumonia, seven both) or coexisting medical conditions (17 cardiovascular, 28 other).

We also found that a proportion of suitable patients (seven of 29) did not want to participate in the home treatment scheme. Some of these simply wanted the reassurance of being in hospital, but two patients declined as they would have lost insurance scheme benefits for inpatient treatment. In summary, our experience supports the findings of Skwarska et al that plans for future assisted discharge schemes should be based on an estimated discharge rate of 20–25% of unselected COPD patients with hospital referrals. We too have found that such patients can be safely treated at home, and that this is acceptable to most patients. We would welcome correspondence from the authors as to whether they encountered similar problems with non-participation due to insurance schemes and, if so, how they addressed them.

AUTHORS’ REPLY We note that Dr Barber and colleagues have used an Acute Respiratory Assessment Service (ARAS) with winter bed money and have had similar results to ours and those of Skwarska et al in Edinburgh. We would like to comment on the proportion of patients referred for admission who are likely to be eligible for this model of care. Dr Barber’s group found that 25% were suitable for supported discharge. In the Edinburgh study 29% were initially considered suitable for home care and in the study recently published from Liverpool 33% were eligible. However, in our study in Glasgow 42% were considered eligible for early supported discharge and this difference may reflect the time when the patients are assessed. In Edinburgh and Liverpool assessment was done on the same day as the patients were assessed on the day after admission. Clinical improvement and increase in forced expiratory volume in one second (FEV1) are maximal in the first 24 hours after admission1 and this may account for the higher FEV1 values and also for the greater eligibility for home care in the Glasgow patients. We now believe that the ARAS model is best employed by assessing patients after 24 hours in hospital. This allows nurses time more effectively and increases the number of patients suitable for home care.

We were interested that two patients in Sheffield did not want to participate in the home treatment scheme but they would have lost insurance scheme benefits. This is not one of the many problems with which we have to cope in the East End of Glasgow.

W MACNEE
Respiratory Medicine Unit, ELEG1, Colt Research Laboratories, Medical School, Edinburgh EH8 9AG, UK
w.macnee@ed.ac.uk

BOOK REVIEW


This popular radiology text is now in its third edition. The challenge for the authors to contain so much information within just over 1000 pages has been successfully met.

The early chapters on plain radiographs are excellent building blocks for any trainee. The growing dependence on high resolution computed tomography (CT) is reflected in several chapters, but this is not at the expense of the plain radiograph. The value of positron emission tomography and magnetic resonance in problem solving are evaluated. CT pulmonary angiography is presented and compared with radionuclide imaging and invasive angiography.

Chapters are written from the viewpoints of both pathological location and radiology. Where the less usual pathologies are discussed—for example, immunologically mediated, drug induced, and transplant related problems—or the more esoteric diseases are described, additional valuable clinical comments are given.

This book can be read from cover to cover; the clarity of the writing and the good illustrations help the pages to fly by. A major strength is that it can be used to help solve those perplexing cases. The index is written with a clear problem orientated approach, but do remember that the spellings are American.

This multi-modality, multi-speciality imaging reference text has been updated. Intended not just for radiologists, our medical, surgical, and allied professional colleagues would be wise to sequester it in their libraries. The illustrations are beautiful, the text is clear, and the references are weighty.—KP
Churg-Strauss syndrome with montelukast

MICHAEL WECHSLER

Thorax 2001 56: 417
doi: 10.1136/thorax.56.5.417a

Updated information and services can be found at:
http://thorax.bmj.com/content/56/5/417.2

These include:

References
This article cites 6 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/56/5/417.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/